ATXA Therapeutics Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Crowdfunding
- Latest Deal Amount
-
$1.03M
- Investors
-
5
ATXA Therapeutics General Information
Description
Developer of a clinical-stage pharma company intended for heart and lung conditions that targets human thromboxane receptor antagonists. The company's medications use a strategy to improve vasodilation and decrease the potential for vasoconstriction by inhibiting the action of the proteinoid thromboxane in cases of thrombosis, renal, prostate, and certain metastatic cancers, as well as other types of pulmonary hypertension and certain types of heart disease, enabling patients to get a proper line of treatment and cure.
Contact Information
Website
www.atxatherapeutics.comCorporate Office
- UCD Conway Institute for Biomolecular & Biomedical Research
- University College Dublin, Belfield
- Dublin 4
- Ireland
Corporate Office
- UCD Conway Institute for Biomolecular & Biomedical Research
- University College Dublin, Belfield
- Dublin 4
- Ireland
ATXA Therapeutics Timeline
ATXA Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Equity Crowdfunding | 30-Oct-2025 | $1.03M | Completed | Clinical Trials - Phase 2 | ||
| 10. Later Stage VC | 16-May-2024 | Completed | Clinical Trials - Phase 2 | |||
| 9. Equity Crowdfunding | 01-May-2024 | Completed | Clinical Trials - Phase 2 | |||
| 8. Grant | 15-Jun-2022 | Completed | Clinical Trials - Phase 2 | |||
| 7. Later Stage VC | 20-Jul-2020 | Completed | Pre-Clinical Trials | |||
| 6. Later Stage VC (Series A) | 01-Apr-2020 | Completed | Pre-Clinical Trials | |||
| 5. Early Stage VC (Series A) | 08-Jan-2018 | Completed | Pre-Clinical Trials | |||
| 4. Early Stage VC | 01-Sep-2016 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC (Series A) | 01-Jul-2015 | $295K | $295K | Completed | Startup | |
| 2. Accelerator/Incubator | 01-May-2015 | Completed | Startup |
ATXA Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Convertible Preference | ||||||||
| A Convertible | ||||||||
| Convertible Preference | 125 | $0.010727 | $1072.71 | $1072.71 | 1x | $1072.71 | 5.34% | |
| Series A | 265 | $0.010727 | $1072.71 | $1072.71 | 1x | $1072.71 | 11.32% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
ATXA Therapeutics Patents
ATXA Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2025242874-A1 | Drug-in-capsule formulations of thromboxane receptor antagonists | Pending | 28-Mar-2024 | ||
| US-20250302848-A1 | Drug-in-capsule formulations of thromboxane receptor antagonists | Pending | 28-Mar-2024 | ||
| WO-2025202463-A1 | Drug-in-capsule formulations of thromboxane receptor antagonists | Pending | 28-Mar-2024 | ||
| AU-2021304808-A1 | Thromboxane receptor antagonist formulations | Pending | 07-Jul-2020 | ||
| CA-3188796-A1 | Thromboxane receptor antagonist formulations | Pending | 07-Jul-2020 | A61K9/1635 |
ATXA Therapeutics Signals
ATXA Therapeutics Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| European Union | Government | |||
| European Innovation Council | Accelerator/Incubator | Minority | ||
| Enterprise Ireland | Growth/Expansion | Minority | ||
| Institutional Investor | Corporation | Minority | ||
| NovaUCD | Accelerator/Incubator | Minority |
ATXA Therapeutics FAQs
-
When was ATXA Therapeutics founded?
ATXA Therapeutics was founded in 2015.
-
Where is ATXA Therapeutics headquartered?
ATXA Therapeutics is headquartered in Dublin, Ireland.
-
What is the size of ATXA Therapeutics?
ATXA Therapeutics has 10 total employees.
-
What industry is ATXA Therapeutics in?
ATXA Therapeutics’s primary industry is Drug Discovery.
-
Is ATXA Therapeutics a private or public company?
ATXA Therapeutics is a Private company.
-
What is the current valuation of ATXA Therapeutics?
The current valuation of ATXA Therapeutics is .
-
What is ATXA Therapeutics’s current revenue?
The current revenue for ATXA Therapeutics is .
-
How much funding has ATXA Therapeutics raised over time?
ATXA Therapeutics has raised $19.9M.
-
Who are ATXA Therapeutics’s investors?
European Union, European Innovation Council, Enterprise Ireland, Institutional Investor, and NovaUCD have invested in ATXA Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process